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Adult Circulatory Support

Extracorporeal Life Support for Cardiogenic Shock With
Either a Percutaneous Ventricular Assist Device or
an Intra-Aortic Balloon Pump
TOMOHIRO NAKAJIMA, YUKI TANAKA, IRENE FISCHER, KUNAL KOTKAR, RALPH J. DAMIANO, Jr.,
MARC R. MOON, MUHAMMAD F. MASOOD, AND AKINOBU ITOH

site occurred more frequently in the ECLS + PVAD group than
the ECLS + IABP group (p < 0.01). Nine patients (18%) in
the ECLS + PVAD group experienced major hemolysis, while
there was no hemolysis in the ECLS + IABP group (p < 0.01).
Careful considerations are required before selecting an additional support to ECLS. ASAIO Journal 2021; 67:25–31.

Extracorporeal life support (ECLS) can result in complications
due to increased left ventricular (LV) afterload. The percutaneous ventricular assist device (PVAD) and intra-aortic balloon
pump (IABP) are both considered to be effective means of LV
unloading. This study describes the efficacy of LV unloading
and related outcomes with PVAD or IABP during ECLS. From
January 2010 to April 2018, all cardiogenic shock patients
who underwent ECLS plus simultaneous PVAD or IABP were
analyzed. Forty-nine patients received ECLS + PVAD, while
91 received ECLS + IABP. At 48 hours, mean pulmonary artery pressure was significantly reduced in both groups [34 mm
Hg to 22, p < 0.01; 32 mm Hg to 21, p < 0.01; ECLS + PVAD
and ECLS + IABP group, respectively]. The two groups had
similar 30 day survival rates [19 patients (39%) vs. 35 (39%),
p = 0.56]. The ECLS + PVAD group had higher incidences
of bleeding at the insertion site [11 (22%) vs. 0, p < 0.01]
and major hemolysis [9 (18%) vs. 0, p < 0.01]. Both groups
had improvement in LV end-diastolic dimension (61 ± 12 mm
to 54 ± 12, p = 0.03; 60 ± 12 mm to 47 ± 10, p < 0.01),
and LV ejection fraction (16 ± 7% to 22 ± 10, p < 0.01;
22 ± 12% to 29 ± 15, p = 0.01). Both ECLS + PVAD and ECLS
+ IABP effectively reduced pulmonary artery pressure and
improved LV function. Bleeding at the PVAD or IABP insertion
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evere cardiogenic shock with hemodynamic derangement
and end-organ hypoperfusion is a potentially fatal condition that
requires immediate medical treatment or mechanical circulatory support (MCS).1 Common acute cardiopulmonary support
methods include veno-arterial extracorporeal life support (VAECLS), percutaneous ventricular assist device (PVAD; Impella,
ABIOMED, Inc., Danvers, MA), intra-aortic balloon pump
(IABP), and TandemHeart (Livanova PLC, London, UK).2 ECLS
with arterial cannulation can possibly increase LV afterload,
precipitating LV distension and pulmonary edema in patients
with poor cardiac function or aortic valve insufficiency.3 Methods used for LV decompression during ECLS include PVAD,
IABP, surgically inserted LV vent through the LV apex or atrium,
and atrial septostomy.4 However, the availability of comparative data is limited regarding the effectiveness of PVAD versus
IABP combined with VA-ECLS. The current study investigated
hemodynamic and echocardiographic data, as well as overall
outcomes and complications in patients with acute cardiogenic
shock treated with VA-ECLS + PVAD versus VA-ECLS + IABP.
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Materials and Methods
Patient Population
We reviewed patients supported with ECLS from January
2010 to April 2018. From this group, patients who developed
cardiogenic shock and were simultaneously supported with
ECLS and PVAD (Impella 2.5, CP, or 5.0) or ECLS and IABP
were enrolled. Those who received ECLS only or multiple
devices but not simultaneously supported were excluded. The
first instance of the concurrent use of PVAD and ECLS at our
institution was in April 2012.
Mechanical Circulatory Support Systems
and Treatment Algorithm
The VA-ECLS modality was used for all patients. The ECLS
circuit consisted of a centrifugal pump (CentriMag; Abbott
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Laboratory, Lake Bluff, IL) and an adult microporous membrane
oxygenator. Central ECLS was conducted via cannulation of the
ascending aorta and right atrium or femoral vein, whereas peripheral ECLS was administered through the femoral artery and
vein cannulation with 15 or 17 Fr for female and 15–19 Fr for
male with 6 Fr sheath insertion to the ipsilateral superficial femoral artery. Multistage percutaneous venous cannulas, size 21
or 25 Fr were inserted percutaneously to the femoral vein. The
PVAD was percutaneously inserted into the common femoral
artery directly, or through a sewn vascular graft to the axillary
artery or the common femoral artery. The IABP was inserted
into the common femoral artery under ultrasound guiding by
the modified Seldinger technique. For those patients who underwent ECLS insertion, the mean arterial pressure was maintained lower than 80 in order to facilitate the LV ejection and
the aortic valve opening. A mild to moderate dose of epinephrine or dobutamine was also used to enhance the LV ejection
with the target arterial pulsatility over 20 mm Hg. IV heparin
drip was utilized with the target prothrombin time between 50
and 90 seconds if there were no signs of bleeding. Once VA
ECLS was established, TTE or TEE was utilized to rule out the
presence of spontaneous echo contrast (smoke sign), which was
a trigger to place an additional venting method, such as IABP or
PVAD based on the availability and attending physicians’ discretion. If the femoral artery was accessible, Impella 2.5 or CP
was utilized. If not, Impella 5.0 was surgically inserted through
the right axillary artery graft. Heparin dose in the purge solution
was reduced to half dose, quarter dose, or none if necessary.
Central ECLS was utilized in postcardiotomy cases where there
was failure to wean the cardiopulmonary bypass after IABP
support. Patients who had their circulatory support initiated
with PVAD or IABP underwent peripheral VA-ECLS insertion
for severe cardiogenic shock and metabolic derangement.
Outcome Variables
The primary outcome was hemodynamic improvement indicated by pulmonary artery pressure (PAP) and central venous
pressure (CVP). Secondary outcomes were MCS decannulation,
transition to a ventricular assist device (LVAD) or heart transplant, and vascular complications during combined support. In
addition, survival to 30 days after combined support initiation
was analyzed. Complications included limb ischemia or bleeding requiring surgical repair at the PVAD or IABP insertion,
major hemolysis, gastrointestinal bleeding, cerebral stroke,
acute kidney injury (AKI), and in-hospital dialysis. Significant
bleeding was defined as bleeding requiring transfusion of
packed red blood cells or reoperation after support initiation.5
Major hemolysis was defined as a serum lactate dehydrogenase
level of greater than 1,000 U/L with the gross appearance of
hemolyzed blood samples.6 Systolic PAP, diastolic PAP, mean
PAP, and CVP were analyzed. The cardiac index, ECLS flow,
and PVAD flow were reported. The pH, levels of lactate, total
bilirubin, lactate dehydrogenase, and creatinine were recorded
to assess LV unloading and end-organ perfusion. These hemodynamic and laboratory values were obtained at the following
time-points: immediately before the initiation of combined support, and 48 hours and 30 days after the initiation of combined
support. Echocardiogram data were collected 1) before combined support and 2) the last echocardiogram assessment either
before weaning or withdrawal of ECLS.

Statistical Analysis
Continuous variables were reported as mean ± standard deviation if normally distributed, and as median (interquartile
range) if non-normally distributed. Normality was examined
by means of both Shapiro–Wilk and Kolmogorov–Smirnov
tests. Continuous variables were compared using the paired
t-test if normally distributed, and the Wilcoxon signed rank test
if non-normally distributed. Categorical variables were compared with the χ2 test. All statistical tests were two-sided, with
alpha set at 0.05 for statistical significance. All statistical analyses were conducted using SPSS (version 25.0, IBM, Armonk,
NY) and R software, version 3.3.3. For the supplemental data
(see Figures and Tables, Supplemental Digital Content 1, http://
links.lww.com/ASAIO/A503), we performed propensity score
matching by choosing the covariates based on the comparison
between the original groups and also their clinical relevance.
The selected variables were: age, body mass index, smoking,
COPD, nonischemic cardiomyopathy, postcardiotomy shock,
left ventricular ejection fraction, and central ECLS. We performed a one-to-one propensity score–matched analysis using
nearest-neighbor matching within a caliper of 0.25 standard
deviation of the logit of the propensity score. We examined
balance in baseline variables using standardized differences,
where more than 25.0% was regarded as imbalanced.
Results
During the study period, a total of 49 patients were simultaneously supported by ECLS and PVAD (ECLS + PVAD group),
while 91 were simultaneously supported by ECLS and IABP
(ECLS + IABP group) (Figure 1). Demographics and baseline
characteristics were reported in Table 1.
The indications for MCS are reported in Table 2. Compared
with the ECLS + PVAD group, the ECLS + IABP group had a
greater incidence of postcardiotomy shock (p = 0.01), postheart transplant graft dysfunction (p = 0.01) and a lower incidence of postpartum cardiomyopathy (p = 0.04). In the
ECLS + PVAD group, 10 patients (20%) received the Impella
2.5, 27 (55%) received the Impella CP, and 12 (24%) received
the Impella 5.0. In the ECLS + IABP group, 12 patients (13%)
received a 34 ml IABP, 55 (60%) received a 40 ml IABP, and 24
(26%) received a 50 ml IABP.
The device selection algorithm is summarized in Figure 2.
The first mechanical support was initiated as follows: PVAD in
32 patients, ECLS in 23 patients, and IABP in 85 patients. All
of the 32 patients supported by PVAD first received ECLS and
17 of the ECLS first patients received PVAD (ECLS + PVAD,
n = 49). All of the IABP first patients received ECLS, and six of
the ECLS first patients underwent IABP insertion subsequently
(ECLS + IABP, n = 91). For in-hospital patients (n = 91), combined support was established within 6 hours after initiation of
the first mechanical support. For 49 patients, the first MCS was
inserted at an outside hospital before the transfer to our hospital; they then received an additional MCS within 24 hours.
Hemodynamic data are summarized in Table 3 and Figure 3.
Compared with the mean PAP before the initiation of support,
the mean PAP after 48 hours was significantly reduced in the
ECLS + PVAD group (p < 0.01) and the ECLS + IABP group
(p < 0.01). The systolic PAP, diastolic PAP, and CVP significantly
changed from before the initiation of support to 48 hours after
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Figure 1. Flow diagram of the patient selection algorithm. Patients with ECLS only or nonsimultaneous ECLS and another MCS were
excluded. ECLS, extracorporeal life support; PVAD, percutaneous ventricular assist device; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support.

support initiation. PVAD flow was 2.5 ± 0.9 L/min in the ECLS
+ PVAD group. There were significant improvements in the pH
level after 48 hours of MCS both in the ECLS + PVAD group
(p < 0.01) and the ECLS + IABP group (p < 0.01). The serum
lactate level was also reduced significantly in both groups after
48 hours of MCS (p < 0.01). There were no significant differences between the two groups with respect to the pH and lactate level at each data point, before, or 48 hours of support.
Although patient numbers were limited regarding cardiac function analysis (Table 3, ECLS + PVAD n = 40, ECLS + IABP n = 70),
improvement of left ventricular ejection fraction (LVEF) and also
reduction in left ventricular end-diastolic diameter (LVEDd) and
Table 1.  Demographics and Baseline Characteristics
Variables
Age, years
Male
Body mass index, kg/m2
Body surface area, m2
Preexisting cardiac disease
Systemic hypertension
Diabetes mellitus
Hyperlipidemia
Smoking
Coronary artery disease
Peripheral artery disease
Chronic obstructive
pulmonary disease
Past cardiothoracic
intervention

ECLS + PVAD ECLS + IABP
p
n = 49 (%)
n = 91 (%)
Values
52.1 ± 13.9
33 (67)
28.7 ± 6.1
2.1 ± 0.3

56.7 ± 12.3
64 (70)
31.0 ± 6.0
2.0 ± 0.2

0.06
0.71
0.04
0.45

11 (22)
14 (29)
10 (20)
17 (35)
25 (51)
4 (8)
1 (2)

27 (30)
21 (23)
20 (22)
11 (12)
51 (56)
4 (4)
10 (11)

0.43
0.54
0.51
< 0.01
0.60
0.45
0.10

21 (43)

42 (46)

0.73

Values are presented as mean ± standard deviation or n (%).
ECLS, extracorporeal life support; PVAD, percutaneous ventricular assist device; IABP, intra-aortic balloon pump.

left ventricular end-systolic diameter (LVESd) were similarly
observed after 48 hours of combined MCS in both groups.
Table 4 summarizes the outcomes and complications. The two
groups had similar rates of survival to 30 days (p = 0.56). Survival
to hospital discharge was observed in 39% of the ECLS + PVAD
group and 30% of the ECLS + IABP group (p = 0.25).
Table 2.  Clinical and Procedural Characteristics Variables
Variables

ECLS + PVAD ECLS + IABP
n = 49 (%)
n = 91 (%) p Value

Indication for circulatory support
 Acute myocardial infarction
 Ischemic cardiomyopathy
 Nonischemic
cardiomyopathy
 Postcardiotomy shock
 Post-heart transplant graft
dysfunction
 Postpartum
cardiomyopathy
 Others
Pre-ECLS cardiac function
 LV ejection fraction, %
 LV end-diastolic
diameter, mm
 LV end-systolic
diameter, mm
Central ECLS
Impella PVAD model
 2.5
 CP
 5.0
IABP

16 (33)
7 (14)
18 (37)

28 (31)
9 (10)
21 (23)

0.85
0.58
0.11

1 (2)
0

16 (18)
11 (12)

0.01
0.01

3 (6)

0

0.04

4 (8)

6 (7)

0.74

16 ± 8
59 ± 11

27 ± 15
57 ± 12

< 0.01
0.38

54 ± 14

47 ± 14

0.07

7 (14)

62 (68)

< 0.01

10 (20)
27 (55)
12 (24)
-

91 (100)

-

Values are presented as mean ± standard deviation or n (%).
ECLS, extracorporeal life support; PVAD, percutaneous ventricular assist device; IABP, intra-aortic balloon pump; LV, left ventricle.
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Figure 2. Mechanical circulatory support device selection algorithm. Out of 49 patients in the ECLS + PVAD group, 32 patients had PVAD
first and 17 patients had ECLS first. Out of 91 patients in the ECLS + IABP group, 85 patients had IABP first, and six patients had ECLS first.

Table 3.  Hemodynamic and Laboratory Data Before, After 48 Hours of Support, and Before Weaning
ECLS + PVAD, n = 49 (%)
Variables
SPAP, mm Hg
DPAP, mm Hg
MPAP, mm Hg
CVP, mm Hg
C.I., L/min/m2
ECLS flow, L/min
PVAD flow, L/min
Laboratory values
 Ph
 Lactate, mmol/L
 Total bilirubin, mg/dL
 LDH, U/L
 Creatine, mg/dL

ECLS + IABP, n = 91 (%)

Before combined
support

48 Hours

p Value

Before combined
support

48 Hours

p Value

47 ± 10
29 ± 8
34 ± 7
14 ± 6
1.3 ± 0.6
-

30 ± 8
19 ± 6
22 ± 7
10 ± 5
…
4.3 ± 1.1
2.5 ± 0.9

< 0.01
< 0.01
< 0.01
< 0.01
-

46 ± 14
25 ± 8
32 ± 10
17 ± 6
1.8 ± 0.8
-

28 ± 9
18 ± 7
21 ± 7
13 ± 5
4.9 ± 1.5
-

< 0.01
< 0.01
< 0.01
< 0.01
-

7.3 ± 0.2
8.1 (4.1–11.5)
1.5 (0.7–2.7)
884 (469–2,586)
1.7 ± 0.8

7.4 ± 0.1
2 (1.5–3.5)
3.3 (1.4–6.2)
1,118(796–1889)
1.8 ± 0.9

< 0.01
0.04
0.07
0.03
0.60

7.3 ± 0.1
7.9 (3.5–12.5)
1.5 (0.8–2.7)
404 (327–634)
1.9 ± 1.2

7.4 ± 0.1
2.3 (1.8–3.6)
2.7 (1.2–5.0)
828 (573–152)
1.8 ± 1.1

< 0.01
0.01
< 0.01
0.02
0.54

ECLS + PVAD, n = 40 (%)
Cardiac Function Data Before Combined
Support and Before Weaning
LV ejection fraction, %
LV end-diastolic diameter, mm
LV end-systolic diameter, mm

ECLS + IABP, n = 70 (%)

Before Combined
Support

Before
Weaning

p Value

Before Combined
Support

Before
Weaning

p Value

16 ± 7
61 ± 12
55 ± 13

22 ± 10
54 ± 12
46 ± 12

< 0.01
0.03
< 0.01

22 ± 12
60 ± 12
52 ± 13

29 ± 15
47 ± 10
37 ± 12

0.01
< 0.01
< 0.01

Values are presented as mean ± standard deviation, median (interquartile range) or n (%).
ECLS, extracorporeal life support; PVAD, percutaneous ventricular assist device; IABP, intra-aortic balloon pump; SPAP, systolic pulmonary artery pressure; DPAP, diastolic pulmonary artery pressure; MPAP, mean pulmonary artery pressure; CVP, central venous pressure; C.I.,
cardiac index; LDH, lactate dehydrogenase; LV, left ventricle.

The causes of death were similar in the two groups. The
main cause of death was cardiac, which occurred in 35% of
the ECLS + PVAD group vs. 38% of the ECLS + IABP group
(p = 0.67). The duration of MCS utilization was as follows:
the ECLS + PVAD group had 4.4 days with Impella 2.5, 7.8
days with Impella CP, and 6.2 days with Impella 5.0 with 6.1
days of ECLS use.
The incidence of death during MCS support was 47% in
both groups. Myocardial recovery was similar (33%) for both
the ECLS + PVAD and ECLS + IABP groups, which allowed for
MCS decannulation without LVAD support; transition to LVAD
occurred in 20% and 16% of the ECLS + PVAD and ECLS + IABP

groups, respectively, while transition to heart transplant
occurred in 0% and 3%, respectively.
Five patients developed limb ischemia due to the PVAD insertion, while three patients developed limb ischemia due to
the IABP insertion (p = 0.09). Bleeding at the PVAD or IABP
insertion site occurred more frequently in the ECLS + PVAD
group than the ECLS + IABP group (p < 0.01). Nine patients
(18%) in the ECLS + PVAD group experienced major hemolysis with combined MCS (three patients with Impella 2.5,
five with Impella CP, and none with Impella 5.0), while there
was no major hemolysis in the ECLS + IABP group (p < 0.01).
The two groups had similar incidences of gastrointestinal
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Figure 3. Box-and-whisker plots of mean pulmonary artery pressure measured before initiation of combined support with ECLS + PVAD
(green) or ECLS + IABP (pink) and after 48 hours of support. In both groups, mean pulmonary artery pressure was significantly reduced after
48 hours of combined support (p < 0.01). The horizontal line in the middle of each box indicates the median; the top and bottom borders of
the box mark the 75th and 25th percentiles, respectively; the whiskers mark the minimum and maximum values.

bleeding, cerebral stroke, acute kidney injury, and in-hospital dialysis.
Propensity score matched group comparison (see Figures
and Tables, Supplemental Digital Content 1, http://links.lww.
com/ASAIO/A503): Propensity score matching was performed
in a 1:1 ratio, resulting in 24 patients in the ECLS + PVAD
group and 24 in the ECLS + IABP group. The patient selection
algorithm is illustrated in Figure E1. Figures E2 and E3 illustrate
the standardized mean differences before and after propensity score matching. Results for the propensity score-matched
patients are reported in Tables E2 and E3.
Discussion
The primary findings of our study were that both PVAD and
IABP similarly reduced PAP and LV diameter when used in
combination with VA-ECLS. ECLS + PVAD and ECLS + IABP
resulted in similar survival rates, but the ECLS + PVAD group
had more complications related to bleeding and major hemolysis than the ECLS + IABP group. To the best of our knowledge,
the current study is the first to compare PVAD versus IABP with
concomitant ECLS.
The use of ECLS may increase the afterload of the LV,2,7
which exacerbates pulmonary edema and leads to worse outcomes.8 Thus, various LV venting strategies have been developed. Tschöpe et al. reported that the increased afterload and
filling pressures can be offset by combining ECLS with a PVAD,
but did not clearly describe precise cardiac echo data, complications, or clinical outcomes.9 Werdan et al. reported that
IABP achieved less LV unloading than PVAD without ECLS.10

Nuding and Werdan reported significantly lower 28 day and
in-hospital mortality rates with IABP/VA-ECLS than with VAECLS alone, with a significant difference in survival.11 However, limited data are available related to PVAD utilization with
ECLS compared to IABP. Our study focused on which device
had the best impact on LV unloading when used simultaneously with ECLS regardless of MCS order (ECLS first or PVAD/
IABP first). We observed a significant reduction in the PAP
and CVP after 48 hours of ECLS + PVAD and ECLS + IABP
support, suggesting that both ECLS + PVAD and ECLS + IABP
achieved similar reductions in ECLS-related pulmonary edema
and LV dimension. The incidence of leg ischemia also tended
to be greater in the ECLS + PVAD group than the ECLS + IABP
group, but this difference did not reach statistical significance.
The current study also found that there were significantly
more bleeding events requiring surgical repair at the insertion
site in the ECLS + PVAD group than the ECLS + IABP group.
Currently, the Impella 2.5 and CP devices need 12 and 14 Fr
sheaths for the insertion and repositioning of the catheter in
the groin, while an IABP requires a sheath size of 7.5 to 8 Fr.
This sheath size difference between devices may particularly
affect patients with cardiogenic shock who are on inotropic
and vasopressor support, have vascular calcifications, or anticoagulation-related coagulopathy or device displacement.12
To address the issue of bleeding from the insertion site, the
design of the repositioning sheath was modified in late 2018.
While this sheath modification should help reduce bleeding,
it is unclear whether it will reduce the occurrence of lower
extremity ischemia. As lower-extremity ischemia leads to detrimental outcomes,13 early recognition is important and requires
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Table 4.  In-hospital Outcomes and Complications

Variables
Survival 30 days
Survival to discharge
Cause of death
Cardiac death
Multiple system organ
failure
Bleeding
Sepsis
Anoxic cerebral event
MCS duration, days
MCS decannulation
Length of hospital stay
Next destination
 Death on MCS
 Myocardial recovery
 Transition to ventricular
assist device
 Transition to heart
transplant
Complications
Limb ischemia caused by
PVAD or IABP
Bleeding caused by PVAD
or IABP
Major hemolysis
Gastrointestinal bleeding
Cerebral stroke
Acute kidney injury
In-hospital dialysis

ECLS + PVAD ECLS + IABP
p
n = 49 (%)
n = 91 (%) value
19 (39)
19 (39)

35 (39)
27 (30)

0.56
0.25

17 (35)
3 (6)

36 (38)
13 (14)

0.67
0.06

2 (4)
3 (6)
4 (8)
7 (3–12)
26 (53)
17 (6–54)

2 (2)
1 (1)
12 (13)
8 (4–13)
48 (53)
23 (9–45)

0.95
0.09
0.60
0.24
0.97
0.80

23 (47)
16 (33)
10 (20)

43 (47)
30 (33)
15 (16)

0.97
0.97
0.56

0

3 (3)

0.20

5 (10)

3 (3)

0.09

11 (22)

0

< 0.01

9 (18)
5 (10)
2 (4)
36 (74)
28 (57)

0
7 (8)
1 (1)
60 (66)
56 (62)

< 0.01
0.75
0.30
0.28
0.72

Values are presented as n (%) or median (interquartile range).
ECLS, extracorporeal life support; PVAD, percutaneous ventricular assist device; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support.

prompt treatment with a distal limb perfusion cannula14 or removal of PVAD. The PVAD carries a risk of hemolysis,15 especially the Impella CP and 2.5 devices with higher RPM setups.
In the current study, major hemolysis occurred in 18% of the
ECLS + PVAD group, but none in the ECLS + IABP group. This
rate of major hemolysis in the ECLS + PVAD group was acceptable in this very sick patient population, but it must be noted
that the PVAD RPM setup was reduced to P2–P5 when it was
used with ECLS due to the reduction in pulmonary circulatory
volume with VA-ECLS. The introduction of MCS resulted in significant improvements in pH and serum lactate in both groups,
indicating adequate perfusion. However, the serum total bilirubin and creatinine did not significantly decrease within 48
hours in either group. This was because it may take longer than
48 hours for serum total bilirubin and creatinine to change
after improvement of hemodynamics.16
The 30 day survival rates in the current study were similar
in both groups: 36% in the ECLS + PVAD group and 33% in
the ECLS + IABP group. The overall survival in this group of
severely deteriorated cardiogenic shock patients treated with
ECLS + PVAD or IABP was not superior compared to previously published data.1,10,17
These results imply that we need a careful consideration on
the LV venting strategy depending on how patients are initially
treated with mechanical assist devices.18 When a patient is already placed on PVAD or IABP and then undergoes VA-ECLS,
the PVAD or IABP may not need to be changed. When a patient
is supported by only VA-ECLS, then spontaneous echo contrast

is seen despite all the effort for the best VA-ECLS management,
either PVAD or IABP can be a choice. Considering the fact that
PVAD is a direct LV venting, this could be the first choice with
a careful attention to the risk of complications, such as leg ischemia, insertion site bleeding, or major hemolysis, in those
institutions which are familiar with the insertion process. Other
methods, such as LV apex surgical venting and intra-atrial septostomy are potential surrogates for the LV unloading.
Limitations
This study has several limitations. The LV unloading method
was selected by multiple physicians during the 9 year study
period and was not randomized. This could introduce selection bias. Although propensity score matching was conducted
in the supplemental analysis, the PAP, cardiac echo data,
and outcomes were similar before and after propensity score
matching. In these analyses, we focused on the differences in
LV unloading by PVAD versus IABP; therefore, the degree of
LV unloading with preload reduction by ECLS only was not
assessed. The two groups differed regarding the incidences of
central and peripheral ECLS, and the indication for MCS; these
intergroup differences were mainly due to the nature of the
support systems and the initial MCS situation. Furthermore,
the order of device introduction varied depending on the case
and location; some cases experienced cardiogenic shock at an
outside hospital and underwent insertion of an IABP alone, immediately followed by transfer to our hospital for further treatment. Multiple providers were involved in the decision-making
process of which MCS to be initiated and added. Finally, the
current study was retrospective and had a small sample; however, this is one of the largest series of patients receiving simultaneous support with PVAD or IABP plus ECLS.
Conclusion
This study demonstrated that both PVAD and IABP similarly
and effectively provided the pulmonary artery pressure reduction with ECLS, resulting in similar survival rates but higher
bleeding complications with PVAD. These findings suggest that
PVAD or IABP can be continued with careful ECLS management when these are placed before VA ECLS. When additional
LV unloading is required during ECLS, either IABP or PVAD
can be utilized. However, a careful consideration is needed to
avoid device-related complications. Further studies are necessary to determine whether these devices improve the outcomes
and survival of patients receiving ECLS.
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